Designed to streamline pharmacy stocking and improve patient access, the compact size features the exact same formulation and cost per mL.

Data from the phase 3 BASIS and BASIS KIDS trials support the expanded indication of this once-weekly subcutaneous non-factor therapy down to age 6.

Data show that orforglipron, a once-daily oral GLP-1 receptor agonist, drives significant, long-term weight reduction in women with obesity or overweight across all 3 stages of menopause: premenopause ...

Kennedy and his advisers have been frustrated that federal access to Americans’ medical records has been limited.